Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
6025.5000 65.00 (1.09%)
NSE May 09, 2025 15:31 PM
Volume: 450.0K
 

6025.50
1.09%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 21.2% YoY to | 995.3 crore (I-direct estimate: | 1151.2 crore) mainly due to lower base of import alert in Q1FY18, currency tailwinds and strong growth in the carotenoid segment EBITDA margins improved 554 bps to 35.4% (I-direct estimate: 36%) mainly due to strong gross margins, lower other expenditure. EBITDA grew 43.7% YoY to | 351.9 crore (I-direct estimate: | 414.4 crore) Net profit grew 50.8% to | 266.2 crore (I-direct estimate: | 308.1...
Divi's Laboratories .. has an average target of 5832.12 from 9 brokers.
More from Divi's Laboratories Ltd.
Recommended